Medical Technology Aristocrat Added to the Best Dividend Stocks List We just added a medical technology giant to the Best Dividend Stocks list today. The company has more than $120 billion in market cap and recently raised its dividend by 13%. The company primarily offers medical devices, although it is diversified across therapeutic areas including cardiac, minimally-invasive restorative therapy and diabetes. Fundamentally, this company has an advantage in the form of an aging US population. This technology giant recently made an acquisition that is likely to realize cost savings of more than $800 million in 2 years.
It is highly profitable and part of the Dividend Aristocrat group of companies – having raised its dividend for 38+ consecutive years. The company can easily afford to raise its dividends by double digits given their modest payout ratio and expected earnings growth of 7% in FY2017. 4 Reasons Why You Should Own This Stock: - In spite of being a "dividend aristocrat," the company has enough room to keep increasing its dividends further.
- Strategic acquisitions are going to result in massive cost savings going forward.
- Demographic dividend in the form of an aging US population favors the company's growth outlook.
- With more than $120 billion in market cap, this company has a wide economic moat.
| Stock Symbol | Unlock | | Price Recommended | Unlock | | Company Name | Unlock | | Date Recommended | 07/08/2016 | | DARS Rating | 3.9 | | Ex-Div Date | Unlock | | Current Yield | 2.03% | | Pay Date | Unlock | All data in the table above updated as of 09/14/2016. UPGRADE TO UNLOCK THIS STOCK! No credit card required! MORE ABOUT THIS STOCK Trailing 5-Year Dividend Payout History - Annualized Growth Over Last 5 Yrs: 9.8%.
As a dividend investor, you need access to the best and safest stocks in the market. Dividend.com’s DARS ratings have been providing you with reliable and profitable stock analysis since 2008, and this addition is no exception. UPGRADE TO UNLOCK THIS STOCK! No credit card required! |
|
|
No comments:
Post a Comment